Lecozotan

Lecozotan
Identifiers
	show IUPAC name
CAS Number	434283-16-6;
PubChem CID	10116877;
ChemSpider	8292400;
UNII	48854OTZ5E;
KEGG	D04683 ;
ChEMBL	ChEMBL372205;
CompTox Dashboard (EPA)	DTXSID20195826 ;
Chemical and physical data
Formula	C28H30ClN5O3
Molar mass	520.03 g·mol−1
3D model (JSmol)	Interactive image;
	show SMILES
	show InChI

Lecozotan is an investigational drug by Wyeth tested for improvement of cognitive functions of Alzheimer's disease patients.^[1] As of June 2008, the first Phase III clinical trial has been completed.^[2]

Method of action[]

Lecozotan is a competitive, selective 5-HT_1A receptor antagonist^[3] which enhances the potassium-stimulated release of acetylcholine and glutamate.^[4]

References[]

^ Spreitzer H (August 13, 2008). "Neue Wirkstoffe - Lecozotan". Österreichische Apothekerzeitung (in German) (17/2007): 805.
^ ClinicalTrials
^ Schechter LE, Smith DL, Rosenzweig-Lipson S, Sukoff SJ, Dawson LA, Marquis K, et al. (September 2005). "Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties". The Journal of Pharmacology and Experimental Therapeutics. 314 (3): 1274–89. arXiv:1506.05421. doi:10.1124/jpet.105.086363. PMID 15951399.
^ Childers Jr WE, Harrison, BL, Abou-Gharbia, MA, Raje, S, Parks, V, Pangalos, MN, Schechter, LE (2007). "Lecozotan Hydrochloride". Drugs of the Future. 32 (5): 399–407. doi:10.1358/dof.2007.032.05.1092901.

This drug article relating to the nervous system is a stub. You can help Wikipedia by .

[1] Spreitzer H (August 13, 2008). "Neue Wirkstoffe - Lecozotan". Österreichische Apothekerzeitung (in German) (17/2007): 805.

[2] ClinicalTrials

[3] Schechter LE, Smith DL, Rosenzweig-Lipson S, Sukoff SJ, Dawson LA, Marquis K, et al. (September 2005). "Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties". The Journal of Pharmacology and Experimental Therapeutics. 314 (3): 1274–89. arXiv:1506.05421. doi:10.1124/jpet.105.086363. PMID 15951399.

[4] Childers Jr WE, Harrison, BL, Abou-Gharbia, MA, Raje, S, Parks, V, Pangalos, MN, Schechter, LE (2007). "Lecozotan Hydrochloride". Drugs of the Future. 32 (5): 399–407. doi:10.1358/dof.2007.032.05.1092901.

[1]

[2]

[3]

[4]

show v t Psychoanaleptics: Anti-dementia agents (ATC code N06D and others)
AChE inhibitor medications	Donepezil Galantamine Ipidacrine Rivastigmine Tacrine
Other medications	Bifemelane Ginkgo folium Meclofenoxate (centrophenoxine) Memantine Nicergoline
Experimental BACE inhibitors	Lanabecestat Verubecestat

Identifiers

show IUPAC name 4-Cyano-N-[(2R)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl]propyl]-N-2-pyridinylbenzamide hydrochloride
CAS Number	434283-16-6
PubChem CID	10116877
ChemSpider	8292400
UNII	48854OTZ5E
KEGG	D04683^Y
ChEMBL	ChEMBL372205
CompTox Dashboard (EPA)	DTXSID20195826
Chemical and physical data
Formula	C₂₈H₃₀ClN₅O₃
Molar mass	520.03 g·mol⁻¹
3D model (JSmol)	Interactive image
show SMILES C[C@H](CN(C1=CC=CC=N1)C(=O)C2=CC=C(C=C2)C#N)N3CCN(CC3)C4=C5C(=CC=C4)OCCO5
show InChI InChI=1S/C28H29N5O3/c1-21(31-13-15-32(16-14-31)24-5-4-6-25-27(24)36-18-17-35-25)20-33(26-7-2-3-12-30-26)28(34)23-10-8-22(19-29)9-11-23/h2-12,21H,13-18,20H2,1H3/t21-/m1/s1 Key:NRPQELCNMADTOZ-OAQYLSRUSA-N